CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02041533
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:17.316640+00:00
Published At: 2017-07-26T00:00:00+00:00
Record Updated At: 2023-03-02
Results Posted At: 2017-07-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stage IV or Recurrent Non-Small Cell Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-03-02"
protocolSection.identificationModule.nctId: "NCT02041533"
protocolSection.identificationModule.officialTitle: "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator\u0027s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-07-26"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.